KRAS and colorectal carcinoma: It was reported that the activation of the AMPK pathway may overcome the drug resistance induced by KRAS mutation in CRC (Ye et al., 2020) and that ROS activated the KRAS/AMPK pathway (Zhao et al., 2019).